Stock Focus. Pioneer Credit (PNC) Tuesday, 12 April 2016
|
|
- Diana Ray
- 5 years ago
- Views:
Transcription
1 Stock Focus Pioneer Credit (PNC) Tuesday, 12 April $2.03 $2.48 $1.69 Share Price $2.82 Positive Neutral Negative Trading Data Last Price $ month range $ $1.85 Market Cap $78m Free Float $48m (62%) 12 month return (historical) 2.8% <insert text here> WHAT SURPRISED? PNC has raised $5.8m in new equity at $1.70 per share (last sale 11 April 2016 $1.695). The funds will be used to accelerate the Company s growth through the acquisition of further parcels of consumer debt. In recent updates PNC has indicated that the PDL purchasing environment is changing, with the intensity of competition waning. This follows a period of higher prices being paid for debt parcels. For the most part this has been an issue for PNC s competitor base, with the Company remaining disciplined with its investment process. Importantly PNC maintains its purchasing guidance of at least $42m in FY16. As such the capital raising supports growth in FY17. This is consistent with previous communications by the company that it expects solid growth in purchases, at appropriate price points, through FY17. EAP forecasts FY17 purchases of $49m, an increase of 17% on FY16. PNC has also reiterated FY16 NPAT guidance of at least $8.8m. WHAT'S CHANGED? Incorporating the share placement our FY16E and FY17 EPS declines 2% and 4% respectively. Despite the purpose of the raising we leave our PDL purchase forecast of $49m for FY17 unchanged at this stage. Valuation remains unchanged at $2.26, with increases in relative multiples since last publication offsetting the dilution of the share placement. WHAT NOW? PNC remains our top pick among the receivables management companies. Importantly the Group differs from its industry peers with an approach premised on understanding its customers circumstances rather than aggressively pursuing collections. As a result the Company typically receives payment over a longer period of time 6-10yrs. However the pay-off is improved recoveries of around 3x PDL investment. In addition, the Company s investment process concentrates on bank related debt and avoids many of the lower quality debt parcels such as account billings (telcos & utilities). As a relatively smaller but growing player, PNC can also benefit from smaller purchases and afford to be more selective in its investment process. With the above in mind we maintain our Positive rating on PNC. <insert text here> Earnings Forecasts Yr to June 13A 14A 15A 16E 17E 18E EBITDA ($m) Rep NPAT ($m) Adj NPAT ($m) EPS ( ) EPS Gth (%) NM NM PER (x) PEG Ratio (x) DPS ( ) Yield (%) Franking (%) ROE (%) 1 15% 14% 16% 18% EV/EBITDA (x) Net Debt/EBITDA (x) Int. Cover (x) (10.8) (8.8) (14.8) (6.1) (5.9) (5.6) Valuation (blended) $2.26 Source: EAP Research PAGE 1 OF 5
2 PNC BALANCE SHEET CAPACITY The business of PDL investment and receivables management is a capital intensive business. Purchases must be made upfront, with the recovery of outstanding principal typically received over the course of next six-ten years. In addition, growth requires every increasing purchases. While we remain comfortable with PNC s debt servicing capacity, there are some limitations to growth with Net Debt/Debt + Equity at around 47% in FY17E. This is based on EAP s forecasts for $49m in PDL purchases for FY17. While we don t forecast revaluations of the PDL portfolio, PNC could also benefit from an upwards revaluation which would also allow for additional headroom. This is a unique and less visible element of the Group s valuation process given PNC adopts a fair value approach to its PDL valuations. In the last two years the Group has benefitted from upwards revaluations which have been carried through the profit and loss. Importantly EBIT interest cover is reasonable at 4.9x FY17E (EAP s forecasts). In short investors should not discount the prospect of future capital raisings, depending on PNC s growth in PDL purchases. Indeed, capital management is a natural function of any growth company in a capital intensive industry. PNC s Forecast PDL Purchases & Gearing Post Placement Source: Company Data, EAP Research PNC s Net DEBT:PDL Value Source: Company Data, EAP Research Forecast PDL Purchases Net Debt / Net Debt + Equity RHS Carrying Value of PDL Net Debt / PDL Value Bank Covenant Net Debt to PDL Value 55% E 2017E 2018E E 2017E 2018E EARNINGS & VALUATION While we have faith that PNC will put the $5.8m raised to work, we have not altered our FY17 purchasing forecasts of $49m. Incorporating the share placement our FY16 and FY17 EPS decline 2% and 4% respectively. Due to change in relative multiples since last publication our valuation remains unchanged at $2.26. EARNINGS REVISIONS Metric Revenue ($m) EBIT ($m) EPS pre Amort'n ( ) DPS ( ) Yr to June Old New % Chg Old New % Chg Old New % Chg Old New % Chg 2016E (2%) E (4%) (5%) 2018E (5%) (7%) Blended Valuation $2.26 $2.26 () Source: Company data, Evans & Partners Research estimates PAGE 2 OF 5
3 FINANCIAL SUMMARY Pioneer Credit PNC As at: 12/04/2016 Recommendation: Positive Share Price $1.70 Year end June 2015A 2016E 2017E 2018E INCOME STATEMENT Sales Revenue $m Consolidated EBITDA $m D&A $m Consolidated EBIT $m Net Interest $m Tax Expense $m Associates/Minorities $m Adj NPAT $m NRIs $m Reported NPAT $m Shares on Issue (end period) m EFPOWA m EPS DPS Franking % GROWTH/PROFITABILITY RATIOS Sales Growth % % 21.1% 18. EBITDA Growth % 62.9% 29.2% % EBIT Growth % 58.6% 29.9% 20.6% 28.6% EPS Growth % 70.4% 12.1% 12.7% 27.3% EBITDA/Sales % 33.3% 35.3% 35.3% 38.2% EBIT/Sales % 30.9% 32.9% 32.8% 35.7% EBIT Interest Cover x (14.8) (6.1) (5.9) (5.6) Tax Rate % 29.5% ROE % 14.8% 14.3% 15.7% 18.1% ROFE % 14.2% 14.2% 14.3% 15.8% CASH FLOW EBITDA $m Change in Working Capital $m (7) Other $m Gross Operating Cash Flow $m Net Interest Paid $m (1) (3) (3) (4) Tax Paid $m (3) (4) (5) (6) Net Operating Cash Flow $m Maintenance Capex $m (1) (1) (1) (1) Free Cash Flow $m Dividends Paid $m (2) (4) (5) (6) Expansionary Capex $m (43) (45) (49) (54) Acquisitions $m Asset Sales $m Dividends Received $m Shares Issues/Buybacks $m Other $m Increase in Net Cash/(Debt) $m (27) (15) (16) (14) GOCF/EBITDA % 76% 101% 101% 101% Total Capex/Sales % 113.4% 98.4% 88.9% 82.9% Total Capex/Depreciation x (46.6) (41.2) (35.5) (33.2) Source: Company data, E&P Research estimates Year end June 2015A 2016E 2017E 2018E VALUATION METRICS PER x P/EG (2YR) x Dividend Yield % % 6.2% 7.6% EV/EBITDA x EV/EBIT x P/FCF x P/BV x BALANCE SHEET Assets Cash $m Working Capital $m PP&E $m Intangibles $m Investments $m Other $m Total Assets $m Liabilities Debt $m Working Capital $m Other $m Total Liabilities $m Equity $m Capital Employed $m Net Debt/(Cash) $m Net Debt/Equity % 58% 72% 89% 99% Net Debt/Debt+Equity % 36.7% 41.8% 47.1% 49.6% Net Debt/EBITDA x Working Capital/Sales % 73% 106% 106% 105% D&A/PP&E % (21.7%) (27.7%) (38.6%) (51.5%) DCF VALUATION $m $/share Risk Free Rate 5.5% Enterprise Value 113 $2.28 Market Risk Premium 5.7% (Net Debt)/Cash (31) ($0.62) Beta 1.20 Franking Credits $0.39 WACC 9.2% DCF Valuation $2.05 Margin Trends 21% Return Trends Gearing & Interest Cover -4 38% 18% % 15% -8 34% 12% % 9% -12 6% % 3% -16 EBITDA/Sales EBIT/Sales ROE ROA ROFE - Reported Net Debt/Net Debt+Equity (%) EBIT Interest Cover (x) Source: Company data, E&P Research estimates PAGE 3 OF 5
4 Positive Neutral Negative Speculative Buy Suspended Not Rated Stock is expected to outperform the S&P/ASX 200 over the coming 24 months Stock expected to perform in line with the S&P/ASX 200 over the coming 24 months Stock is expected to underperform the S&P/ASX 200 over the coming 24 months Stock has limited history from which to derive a fundamental investment view or its prospects are highly dependent on event risk, eg. Successful exploration, scientific breakthrough, high commodity prices, regulatory change, etc. Stock is temporarily suspended due to compliance with applicable regulatory and/or Evans & Partners policies in circumstances where Evans & Partners is acting in an advisory capacity. Stock is not included in our investment research universe. Research Criteria Definitions Recommendations are primarily determined with reference to how a stock ranks relative to the S&P/ASX 200 on the following criteria: Valuation Earnings Outlook Earnings Momentum Shareholder Returns Debt Servicing Capacity Cyclical Risk Industry Quality Financial Transparency Rolling 12 month prospective multiples (composite of Price-to-Earnings Ratio, Dividend Yield and EV/EBITDA), or long-term NPV for resource stocks. Forecast 2 year EPS growth. Percentage change in the current consensus EPS estimate for the stock (rolling 1 year forward basis) over the consensus EPS estimate for the stock 3 months ago. Composite of forecast ROE (rolling 1 year forward basis) and the percentage change in ROE over 2 years. Rolling 12 month EBIT Interest Cover ratio. Qualitative assessment of the 2 year outlook for a stock/industry s profit cycle. Qualitative assessment of an industry s growth/returns potential and company specific management capability. If we don t understand it, we won t recommend it. For stocks where Evans & Partners does not generate its own forecasts, Bloomberg consensus data is used. Analysts can introduce other factors when determining their recommendation, with any material factors stated in the written research where appropriate. PAGE 4 OF 5
5 This document is provided by Evans and Partners ABN , holder of AFSL Please see our website at for important information regarding Evans and Partners research. The information is general advice only and does not take into consideration an investor s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor s objectives, financial situation and needs. If the advice relates to a financial product that is the subject of a Product Disclosure Statement (e.g. unlisted managed funds) investors should obtain the PDS and consider it before making any decision about whether to acquire the product. The material contained in this document is for information purposes only and does not constitute an offer, solicitation or recommendation with respect to the purchase or sale of securities. It should not be regarded by recipients as a substitute for the exercise of their own judgment. Investors should be aware that past performance is not an infallible indicator of future performance and future returns are not guaranteed. Any opinions and/or recommendations expressed in this material are subject to change without notice and Evans and Partners is not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Evans and Partners. Evans and Partners and its respective officers and associates may have an interest in the securities or derivatives of any entities referred to in this material. Evans and Partners does, and seeks to do, business with companies that are the subject of its research reports. Company AUI AYUHB BENPF CIE CGL DUI EAI IGL MGC MQGPB NAB SWM TGG TOX Nature of Relationship The Issuer has appointed Evans and Partners as Broker to an on-market buy-back. Accordingly, Evans and Partners is unable to give Sellers advice in respect to a sale of this security. Evans and Partners has been appointed as Placement Agent in respect of the company s renounceable rights issue and will receive fees for acting in this capacity. A director of Evans and Partners Pty Ltd is a director of The Citadel Group Limited. The Issuer has appointed Evans and Partners as Broker to an on-market buy-back. Accordingly, Evans and Partners is unable to give Sellers advice in respect to a sale of this security. Evans and Partners arranged, managed or co-managed a public offering of the company or its affiliates in the past 12 months A director of Evans and Partners Pty Ltd is a director of Seven West Media Limited. Evans and Partners Pty Ltd was appointed as Sponsoring Broker in relation to the 1 for 4 pro-rata entitlement offer (and any subsequent shortfall) of Templeton Global Growth Fund Limited (TGG) and will receive fees for acting in this capacity. Evans and Partners arranged, managed or co-managed a public offering of the company or its affiliates in the past 12 months I, Simon Fitzgerald, hereby certify that all the views expressed in this report accurately reflect my personal views about the subject investment theme and/or company securities. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. I, Simon Fitzgerald, and/or entities in which I have a pecuniary interest, have an exposure to the following securities and/or managed products: N/A Except for any liability which cannot be excluded, Evans & Partners, its directors, employees & agents accept no liability or responsibility whatsoever for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material. All information is correct at the time of publication; additional information may be available upon request. PAGE 5 OF 5
Result Focus. Pioneer Credit (PNC) Monday, 27 February 2017
Result Focus Pioneer Credit (PNC) Monday, 27 February 2017. $2.25 $2.71 $1.94 Share Price $3.02 Positive Neutral Negative Trading Data Last Price $2.07 12 month range $1.60 - $2.09 Market Cap $101m Free
More informationResult Focus. Osprey Medical Inc. (OSP.ASX) Last price $0.38 Valuation $0.58. Thursday, 25 January 2018
Result Focus Osprey Medical Inc. (OSP.ASX) Thursday, 25 January 2018 Last price $0.38 Valuation $0.58 TSR Upside to valuation 51.8% Dividend yield 0.0% Expected total SH return 51.8% Trading Data Last
More informationOrbis Gold Ore Zone December 2014
. $0.32 $0.57 $0.89 Share Price $1.13 Positive Neutral Negative RECOMMENDATION: NEUTRAL (WAS SPECULATIVE BUY) Orbis was recently approached by Semafo with a proposed offer for the company of $A0.65. The
More informationResult Focus. Osprey Medical Inc. (OSP.ASX) Last price $0.15 Valuation $0.37. Tuesday, 30 October 2018
Result Focus Osprey Medical Inc. (OSP.ASX) Tuesday, 30 October 2018 Last price $0.15 Valuation $0.37 TSR Upside to valuation 146.8% Dividend yield 0.0% Expected total SH return 146.8% Trading Data Last
More informationBoart Longyear. Earnings and target price revision. No change. Price catalyst. Action and recommendation
AUSTRALIA BLY AU Price (at 08:01, 12 Sep 2013 GMT) Neutral A$0.50 Valuation A$ 0.71 - DCF (WACC 10.1%, beta 1.5, ERP 0.1%, RFR 0.1%, TGR 0.0%) 12-month target A$ 0.56 12-month TSR % +12.0 Volatility Index
More informationSilver Chef. Capital raising A$7.71 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA SIV AU Price (at 08:50, 21 Mar 2017 GMT) Neutral A$7.71 Valuation - PER A$ 6.68 12-month target A$ 6.68 12-month TSR % -7.4 Volatility Index Medium GICS sector Capital Goods Market cap A$m 278
More informationSG Fleet Group. Another UK acquisition. Earnings and target price revision
AUSTRALIA SGF AU Price (at 08:26, 30 Nov 2016 GMT) Outperform A$3.23 Valuation - PER A$ 3.96-4.22 12-month target A$ 4.37 12-month TSR % +41.0 Volatility Index High GICS sector Commercial & Professional
More informationBUY SHARE PRICE CASH EARNINGS ($M) COMPANY DATA & RATIOS
BUY 0.11 0.39 0.69 SHARE PRICE CASH EARNINGS ($M) COMPANY DATA & RATIOS CONTENTS Competitors Products Sales channels Pricing Model INVESTMENT THESIS COMPANY OVERVIEW INDUSTRY OVERVIEW COMPETITORS BOARD
More informationSG Fleet Group % growth in FY17. Earnings and target price revision. Price catalyst. Catalyst: Results and contract wins.
AUSTRALIA SGF AU Price (at 07:57, 27 Oct 2016 GMT) Outperform A$3.85 Valuation - PER A$ 3.92-4.18 12-month target A$ 4.37 12-month TSR % +18.1 Volatility Index Medium GICS sector Commercial & Professional
More informationEclipx Group. Highlights its funding flexibility A$3.77 AUSTRALIA. Event. Impact. Earnings and target price revision.
AUSTRALIA ECX AU Price (at 02:49, 15 Dec 2016 GMT) Outperform A$3.77 Valuation - PER A$ 3.53-3.78 12-month target A$ 4.22 12-month TSR % +16.3 Volatility Index Low/Medium GICS sector Diversified Financials
More informationPlatinum Asset Management
AUSTRALIA PTM AU Price (at 06:10, 11 Jul 2016 GMT) Neutral A$5.52 Valuation A$ - DCF (WACC 9.3%, beta 1.2, ERP 5.0%, RFR 3.3%) 5.19 12-month target A$ 5.36 12-month TSR % +2.6 Volatility Index Low/Medium
More informationVista Group International
NEW ZEALAND VGL NZ Price (at 03:15, 26 Feb 2015 GMT) Outperform NZ$4.35 Valuation NZ$ 4.31 - DCF (WACC 9.9%, beta 1.0, ERP 7.0%, RFR 4.0%, TGR 2.0%) 12-month target NZ$ 4.75 12-month TSR % +9.5 Volatility
More informationCardno. Tough half over A$2.88 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA CDD AU Price (at 04:53, 17 Feb 2015 GMT) Neutral A$2.88 Valuation - Sum of Parts A$ 2.80-3.43 12-month target A$ 3.12 12-month TSR % +18.4 Volatility Index Medium GICS sector Capital Goods Market
More informationSouthern Cross Media. Streamlining ahead of reform? A$1.37 AUSTRALIA
AUSTRALIA SXL AU Price (at 05:10, 27 Mar 2017 GMT) Neutral A$1.37 Valuation A$ - DCF (WACC 8.0%, beta 1.2, ERP 5.0%, RFR 3.3%) 1.39 12-month target A$ 1.30 12-month TSR % +0.8 Volatility Index Medium GICS
More informationAuckland International Airport
NEW ZEALAND AIA NZ Price (at 04:00, 27 Nov 2013 GMT) Neutral NZ$3.42 Valuation NZ$ 3.37 - DCF (WACC 8.0%, beta 0.9, ERP 7.0%, RFR 4.3%, TGR 3.0%) 12-month target NZ$ 3.37 12-month TSR % +2.6 Volatility
More informationSeek. Progresses Zhaopin privatisation A$16.33 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA SEK AU Price (at 06:33, 07 Apr 2017 GMT) Outperform A$16.33 Valuation - Sum of Parts A$ 16.77 12-month target A$ 16.50 12-month TSR % +3.9 Volatility Index Low/Medium GICS sector Commercial &
More informationFisher & Paykel Healthcare
NEW ZEALAND FPH NZ Price (at 05:00, 10 Jul 2015 GMT) Outperform NZ$7.03 Valuation NZ$ 7.39 - DCF (WACC 8.8%, beta 0.9, ERP 7.0%, RFR 4.5%, TGR 2.0%) 12-month target NZ$ 7.80 12-month TSR % +13.1 Volatility
More informationTox Free Solutions. Winning work again A$2.34 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA TOX AU Price (at 05:10, 30 Nov 2016 GMT) Outperform A$2.34 Valuation - EV/EBITDA A$ 2.52-3.07 12-month target A$ 2.79 12-month TSR % +23.1 Volatility Index Medium GICS sector Commercial & Professional
More informationOrocobre. Upside exposure fading. Earnings and target price revision. Price catalyst. Catalyst: Update on projects or Q1 report
AUSTRALIA ORE AU Price (at 5:11, 28 Feb 217 GMT) Neutral A$3.8 Valuation - DCF (WACC 1.%) A$ 1.34 12-month target A$ 3.17 12-month TSR % +2.9 Volatility Index High GICS sector Materials Market cap A$m
More informationIOOF. Positive flows in 1Q17. FUM and Net Flows for September Qtr Source: Company data, Macquarie Research, Oct 2016.
AUSTRALIA IFL AU Price (at 06:35, 26 Oct 2016 GMT) Outperform A$8.34 Valuation A$ - DCF (WACC 8.8%, beta 1.1, ERP 5.0%, RFR 3.3%) 8.74 12-month target A$ 9.00 12-month TSR % +14.3 Volatility Index Low/Medium
More informationUGL. Driving growth in DTZ. Earnings and target price revision. No change. Price catalyst. Action and recommendation
AUSTRALIA AU Price (at 08:17, 03 Sep 2012 GMT) Underperform A$10.52 Volatility index Low 12-month target A$ 11.08 12-month TSR % +12.0 Valuation A$ - DCF (beta 1.1, ERP 5.0%, RFR 6.0%, TGR 2.5%) 15.09
More informationTelstra Corporation. Vodafone better, but far from good A$6.43 AUSTRALIA. Event. Impact. Earnings and target price revision.
AUSTRALIA TLS AU Price (at 11:23, 21 Jul 2015 GMT) Neutral A$6.43 Valuation A$ 6.37 - DCF (WACC 6.8%, beta 0.8, ERP 5.0%, RFR 3.8%, TGR 1.2%) 12-month target A$ 6.30 12-month TSR % +3.3 Volatility Index
More informationLUCISANO MEDIA GROUP. New partner for Lucisano. Buy (maintained) Company Update
LUCISANO MEDIA GROUP Company Update Buy (maintained) 5:30PM MARKET PRICE: EUR2.82 TARGET PRICE: EUR3.40 (unchanged) Entertainment Data Shares Outstanding (m): 14.88 Market Cap. (EURm): 41.96 Enterprise
More informationOz Minerals. Solid start to the year A$5.62 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA OZL AU Price (at 6:24, 21 Apr 216 GMT) Underperform A$5.62 Valuation A$ - DCF (WACC 1%, beta 1.4, ERP 5.%, RFR 3.8%) 4.61 12-month target A$ 4.6 12-month TSR % -15.5 Volatility Index High GICS
More informationWINDLAB LTD HOLD. Lakeland financial close delayed again. Downgrade to HOLD. COMPANY UPDATE EVENT IMPACT INVESTMENT VIEW
WINDLAB LTD HOLD Lakeland financial close delayed again. Downgrade to HOLD. Utilities / Renewable Electricity 7 November 2018 COMPANY UPDATE Ticker WND Stock Price $1.180 Target Price $1.350 Forecast Capital
More informationRamsay Health Care. France begins to bite A$66.37 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst
AUSTRALIA RHC AU Price (at 06:11, 06 Aug 2015 GMT) Neutral A$66.37 Valuation A$ 64.54 - DCF (WACC 8.1%, beta 1.1, ERP 5.0%, RFR 3.8%, TGR 3.0%) 12-month target A$ 70.00 12-month TSR % +7.3 Volatility Index
More informationONEVIEW HEALTHCARE PLC
ONEVIEW HEALTHCARE PLC BUY 2017 Result Green Shoots Emerging Health Care Equipment & Services / Health Care Technology 28 February 2018 COMPANY UPDATE Ticker ONE Stock Price $1.900 Target Price $3.04 Forecast
More informationSpotless Group Holdings
AUSTRALIA SPO AU Price (at 05:45, 31 Jan 2017 GMT) Neutral A$0.94 Valuation - Peer multiples A$ 1.02 12-month target A$ 1.02 12-month TSR % +18.3 Volatility Index High GICS sector Commercial & Professional
More informationQBE Insurance. QBE ANZ performance: LMI vs. Excl. LMI (A$m) Source: Company data, Macquarie Research, April 16. Earnings and target price revision
AUSTRALIA QBE AU Price (at 10:44, 27 Apr 2016 GMT) Neutral A$11.19 Valuation A$ - DCF (WACC 9.3%, beta 1.1, ERP 5.0%, RFR 3.8%) 11.34 12-month target A$ 12.00 12-month TSR % +12.7 Volatility Index Low/Medium
More informationConsolidated Operations Group (COG)
Consolidated Operations Group (COG) 10 April 2018 Outperform Upgrade to OUTPERFORM - Inflection point nearing $0.10 Jason Palmer jpalmer@taylorcollison.com.au +618 8217 3965 Summary (AUD) Market Capitalisation
More informationOz Minerals. On track to meet guidance A$6.51 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA OZL AU Price (at 08:20, 22 Jul 2016 GMT) Underperform A$6.51 Valuation A$ - DCF (WACC 9.0%, beta 1.4, ERP 5.0%, RFR 3.3%) 4.31 12-month target A$ 5.00 12-month TSR % -21.4 Volatility Index High
More informationResetting expectations
Company update 13 May 2016 TPI ENTERPRISES (TPE) Resetting expectations We retain a BUY rating with a revised 12-month price target of $3.21 p/sh. We assess market conditions to imply a more gradual ramp
More informationAutomotive Holdings Group
AUSTRALIA AHG AU Price (at 06:14, 11 Aug 2016 GMT) Outperform A$4.61 Valuation - EV/EBITA A$ 4.09-4.63 12-month target A$ 4.36 12-month TSR % -0.2 Volatility Index Low GICS sector Retailing Market cap
More informationRegional Express Holdings Ltd REX
20 February 2006 REX $1.15 Analyst Ken Fleming (613) 6224 8511 ken.fleming@tricom.com.au Max Wheeler (613) 6224 9899 Fully diluted shares on issue 115.0M Market cap A$132.3M Performance & Valuation Last
More informationDowner EDI Two out of three ain t bad Event
AUSTRALIA DOW AU Price (at 06:26, 01 Dec 2016 GMT) Outperform A$6.08 Valuation - Sum of Parts A$ 5.69-6.38 12-month target A$ 6.40 12-month TSR % +9.6 Volatility Index Medium GICS sector Commercial & Professional
More informationSims Metal Management
AUSTRALIA SGM AU Price (at 5:11, 17 Nov 215 GMT) Outperform A$7.19 Valuation - EV/EBIT A$ 8.49-9.6 12-month target A$ 8.9 12-month TSR % +26.6 Volatility Index Medium GICS sector Materials Market cap A$m
More informationSandfire Resources. Swings to net cash A$5.34 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA SFR AU Price (at 6:11, 7 Jul 216 GMT) Outperform A$5.34 Valuation A$ - DCF (WACC 9.%, beta 1.4, ERP 5.%, RFR 3.3%) 5.82 12-month target A$ 6.1 12-month TSR % +18.3 Volatility Index Medium GICS
More informationKingsgate Consolidated
AUSTRALIA KCN AU Price (at 6:11, 31 Jul 215 GMT) Underperform A$.67 Valuation A$ - DCF (WACC 12.%, beta 1.6, ERP 5.%, RFR 3.8%).3 12-month target A$.3 12-month TSR % -54.9 Volatility Index Very High GICS
More informationChallenger. Normalised margin trends expected to decline. Earnings and target price revision. Price catalyst. Action and recommendation
1H13E 2H13E 1H14E 2H14E 1H15E 2H15E AUSTRALIA CGF AU Price (at CLOSE#, 20 Aug 2012) Outperform A$3.76 Volatility index Low 12-month target A$ 4.57 12-month TSR % +26.4 Valuation - Sum of Parts A$ 4.57
More informationNoni B (NBL) SFH acquisition could be up to 60% EPS accretive. Key points. Risks and catalysts
Date Theme Company Update Company Noni B (NBL) SFH acquisition could be up to 6 EPS accretive Press reports today (Australian) suggest Noni B is a potential acquirer of Specialty Fashion Group (SFH), in
More informationSingTel. Earnings and target price revision. Price catalyst. Action and recommendation. Maintain Outperform.
AUSTRALIA SGT AU Price (at 05:10, 06 Dec 2012 GMT) Outperform A$2.59 Volatility index Low 12-month target A$ 2.81 12-month TSR % +14.6 Valuation - Sum of Parts A$ 2.81 GICS sector Telecommunication Services
More informationPRICE $1.30 Regional Express Holdings Ltd REX
16 November 2006 PRICE $1.30 Regional Express Holdings Ltd REX Analyst Ken Fleming (03) 6224 8511 ken.fleming@tricom.com.au Max Wheeler (03) 6224 9899 Fully diluted shares on issue 115M Market cap A$133M
More informationOrigin Energy. 4Q Production. ORG reported its 4 th quarter production report, following on ConocoPhilips quarterly result.
AUSTRALIA ORG AU Price (at 06:11, 30 Jul 2015 GMT) Neutral A$11.35 Valuation A$ 12.79 - DCF (WACC 10.3%, beta 1.3, ERP 5.0%, RFR 3.8%, TGR 2.0%) 12-month target A$ 12.89 12-month TSR % +18.1 Volatility
More informationNoni B (NBL) BUY: FY18e EBITDA +12.8% Key points. Risks and catalysts
Date 09 January 2018 Theme Company Update Company Noni B (NBL) BUY: FY18e EBITDA +12.8% NBL provided a positive 1H18 trading update today, advising LFL sales growth of 3.0% (1.5% in 1H17) and EBITDA of
More informationFairfax / REA Group. No housing boom here. A$0.81 Valuation A$ Sum of Parts 12-month target A$ month TSR % +16.0
AUSTRALIA FXJ AU Price (at 05:11, 03 Nov 2016 GMT) Outperform A$0.81 Valuation A$ 0.88 - Sum of Parts 12-month target A$ 0.90 12-month TSR % +16.0 Volatility Index Low/Medium Market cap A$m 1,863 30-day
More informationPilbara Minerals (PLS AU) Ramp-up gaining traction
17 January 219 Australia EQUITIES PLS AU Price (at 5:1, 16 Jan 219 GMT) Outperform A$.7 Valuation A$ 1.11 - DCF (WACC 1.%, beta 1.6, ERP 5.%, RFR 3.8%) 12-month target A$ 1.2 12-month TSR % +72.7 Volatility
More informationEarnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA TLS AU Price (at 13:07, 19 Apr 2012 GMT) Outperform A$3.39 Volatility index Low 12-month target A$ 3.55 12-month TSR % +13.0 Valuation A$ - DCF (WACC 9.6%, beta 0.9, ERP 6.0%, TGR 1.0%) 3.55
More informationPerseus Mining. Revised Sissingué plan A$0.31 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA PRU AU Price (at 5:1, 31 Mar 217 GMT) Neutral A$.31 Valuation A$ - DCF (WACC 1.%, beta.4, ERP 5.%, RFR 3.3%).35 12-month target A$.32 12-month TSR % +3.2 Volatility Index Very High GICS sector
More informationNuplex Industries. Should benefit from a weak Kiwi NZ$4.55 NEW ZEALAND. Event. Impact. Earnings and target price revision.
NEW ZEALAND NPX NZ Price (at 05:00, 31 Jul 2015 GMT) Outperform NZ$4.55 Valuation NZ$ 4.40 - DCF (WACC 12.5%, beta 1.4, ERP 7.0%, RFR 4.5%, TGR 2.0%) 12-month target NZ$ 4.75 12-month TSR % +10.6 Volatility
More informationMEDICAL DEVELOPMENTS INTERNATIONAL LTD
MEDICAL DEVELOPMENTS INTERNATIONAL LTD No pain in Germany HOLD Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals 6 April 2018 COMPANY UPDATE Ticker MVP Stock Price $7.10 Target Price $8.08
More informationCochlear. Roberts replaced A$88.66 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA COH AU Price (at 06:47, 26 May 2015 GMT) Outperform A$88.66 Valuation A$ 81.19 - DCF (WACC 8.0%, beta 1.0, ERP 5.0%, RFR 3.8%, TGR 3.0%) 12-month target A$ 95.00 12-month TSR % +9.8 Volatility
More informationNoni B (NBL) BUY: Acquisition may signal the end of discounting in mature womenswear. Key points. Risks and catalysts
Date Theme Company Update Company Noni B (NBL) BUY: Acquisition may signal the end of discounting in mature womenswear Noni B Group has agreed to acquire 5 brands from Specialty Fashion Group. Funded by
More informationEarnings and target price revision. Price catalyst. Catalyst: 1H14 result in February Action and recommendation
AUSTRALIA CBA AU Price (at 06:10, 10 Sep 2013 GMT) Neutral A$73.63 Valuation A$ - DCF (WACC 10.3%, beta 1.0, ERP 5.0%, RFR 5.5%) 50.40 12-month target A$ 66.15 12-month TSR % -5.0 Volatility Index Low
More informationNanosonics Limited. Australia Health Care Equipment & Supplies. Growth outlook unchanged. Earnings Forecasts. Source Company, LINWAR Research
LINWAR Securities 30 August 2011 Nanosonics Limited Australia Health Care Equipment & Supplies Outperform (Unchanged) Price: Target Price: Stock's expected return (12mth) $0.57 $1.20 Capital growth 112.4%
More information3P Learning. Coming to America... A$2.55 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA 3PL AU Price (at 09:19, 02 Mar 2015 GMT) Outperform A$2.55 Valuation - DCF A$ 2.65-3.35 12-month target A$ 3.00 12-month TSR % +18.9 Volatility Index Low/Medium GICS sector Consumer Services
More informationSirtex Medical. Healthy dose sales. Earnings and target price revision. Price catalyst. Catalyst: FY16 result on the 24th of August
AUSTRALIA SRX AU Price (at CLOSE#, 11 Jul 2016) Outperform A$27.88 Valuation A$ 37.93 - DCF (WACC 9.0%, beta 1.2, ERP 5.0%, RFR 3.3%, TGR 1.5%) 12-month target A$ 38.00 12-month TSR % +37.4 Volatility
More informationGreencross. Check up. We review the outlook for GXL. Earnings and target price revision. Price catalyst. Catalyst: FY15/6 results
AUSTRALIA GXL AU Price (at 09:46, 13 Jul 2015 GMT) Outperform A$5.00 Valuation - EV/EBITA A$ 7.15-8.05 12-month target A$ 7.50 12-month TSR % +53.9 Volatility Index Medium GICS sector Health Care Equipment
More informationFilling in the gaps. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA PGH AU Price (at 06:11, 16 Jun 2015 GMT) Neutral A$4.45 Valuation - Peers' Multiples A$ 4.70 12-month target A$ 4.70 12-month TSR % +10.3 Volatility Index Low GICS sector Materials Market cap
More informationAUSTRALIA Price Event Valuation A$ month target A$ 5.20
AUSTRALIA VOC AU Price (at 05:10, 22 Feb 2017 GMT) Outperform A$4.81 Valuation A$ 5.02 - DCF (WACC 7.7%, beta 1.2, ERP 5.0%, RFR 3.3%, TGR 1.0%) 12-month target A$ 5.20 12-month TSR % +12.2 Volatility
More informationRegis Resources. Strong 1H15 result A$1.29 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA RRL AU Price (at 7:29, 13 2 GMT) Outperform A$1.29 Valuation A$ - DCF (WACC 9.%, beta 1.5, ERP 5.%, RFR 3.8%) 1.68 12-month target A$ 1.7 12-month TSR % +37.2 Volatility Index High GICS sector
More informationNEW ZEALAND Price Valuation NZ$ 1.74 Event 12-month target NZ$ month TSR % -10.1
NEW ZEALAND GNE NZ Price (at 05:06, 24 Feb 2015 GMT) Underperform NZ$2.20 Valuation NZ$ 1.74 - DCF (WACC 8.1%, beta 0.6, ERP 7.0%, RFR 3.6%, TGR 2.1%) 12-month target NZ$ 1.82 12-month TSR % -10.1 Volatility
More informationFisher & Paykel Healthcare
NEW ZEALAND FPH NZ Price (at 03:59, 16 Mar 2015 GMT) Outperform NZ$6.63 Valuation NZ$ 6.86 - DCF (WACC 8.8%, beta 0.9, ERP 7.0%, RFR 4.5%, TGR 2.0%) 12-month target NZ$ 7.25 12-month TSR % +11.6 Volatility
More informationAsset revaluation driven by almonds
Company update 20 July 2015 RURAL FUNDS GROUP (RFF) Asset revaluation driven by almonds We retain a BUY rating with a 12-month target of $1.15 p/unit. RFF is a listed property trust with a portfolio of
More informationGeneration Healthcare REIT
AUSTRALIA GHC AU Price (at 06:13, 24 Aug 2015 GMT) Neutral A$1.65 Valuation - Sum of Parts A$ 1.51-1.59 12-month target A$ 1.59 12-month TSR % +1.8 Volatility Index Low GICS sector Real Estate Market cap
More informationAppen Limited (APX-AU) 29 August 2017
Appen Limited (APX-AU) 29 August 2017 Pricing in another Upgrade Marketperform Adam Dellaverde adamd@taylorcollison.com.au +618 8217 3923 +6403 013 032 Summary Market capitalisation ($m) $438.7 Share price
More informationAtCor Medical Holdings Limited (ACG)
Volume (million) AtCor Medical Holdings Limited (ACG) 30 March 2015 Speculative Buy Value Creation Ahead Post CPT1 Code Award $0.20 Marcus Hamilton mhamilton@taylorcollison.com.au +61 2 9210 1317 Summary
More informationIndependence Group NL
AUSTRALIA IGO AU Price (at 12:29, 26 Oct 216 GMT) Outperform A$4.25 Valuation A$ - DCF (WACC 8.4%, beta 1.2, ERP 5.%, RFR 3.3%) 3.98 12-month target A$ 5. 12-month TSR % +2.2 Volatility Index High GICS
More informationFund Managers. Aust. Fund managers review & rank AUSTRALIA. Event. Stock Views
AUSTRALIA 4 February 2016 Macquarie Securities (Australia) Limited Aust. Fund managers review & rank Event We review and rank the listed Australian under Macquarie Securities coverage, assessing fund performance,
More informationMeridian Energy. On tax depreciation NZ$2.08 NEW ZEALAND. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
NEW ZEALAND MEL NZ Price (at 05:00, 13 Jul 2015 GMT) Outperform NZ$2.08 Valuation NZ$ 2.50 - DCF (WACC 7.8%, beta 0.6, ERP 7.0%, RFR 3.6%, TGR 2.0%) 12-month target NZ$ 2.60 12-month TSR % +31.7 Volatility
More informationNIB Holdings. Lowest in 4 years still enough A$3.72 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst
AUSTRALIA NHF AU Price (at 09:52, 02 Mar 2016 GMT) Outperform A$3.72 Valuation A$ 3.85 - DCF (WACC 8.5%, beta 1.0, ERP 5.0%, RFR 3.8%, TGR 2.5%) 12-month target A$ 4.00 12-month TSR % +11.7 Volatility
More informationAged Care. Propco sale & lease back A$2.71 A$5.75 A$6.15 AUSTRALIA. Event. Impact. Outlook
AUSTRALIA JHC AU Price (at 06:10, 27 Apr 2015 GMT) Outperform A$2.71 Valuation A$ 2.97 - DCF (WACC 9.1%, beta 1.1, ERP 5.0%, RFR 4.5%, TGR 2.3%) 12-month target A$ 3.00 12-month TSR % +14.7 Volatility
More informationPanAust. Larger impairment and dividend cut A$1.35 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst
AUSTRALIA PNA AU Price (at 7:6, 19 Feb 215 GMT) Outperform A$1.35 Valuation A$ - DCF (WACC 11.%, beta 1.7, ERP 5.%, RFR 3.8%) 1.73 12-month target A$ 1.7 12-month TSR % +25.9 Volatility Index High GICS
More informationCIMIC Group. Earnings and target price revision. No change. Price catalyst. Catalyst: Q1 earnings 13 April. Action and recommendation
AUSTRALIA CIM AU Price (at 05:10, 31 Mar 2017 GMT) Outperform A$35.93 Valuation A$ 42.69 - DCF (WACC 8.5%, beta 1.4, ERP 5.0%, RFR 3.3%, TGR 2.0%) 12-month target A$ 42.50 12-month TSR % +22.0 Volatility
More information2014 E 2015 E 2016 E 2017 E
Equity Research 4 December 2014 Interpump Group Hydraulics M&A may power growth Rating BUY Target price EUR13 Interpump is up 25% since the beginning of the year, bolstered by strong interim results and
More informationPetro Rabigh Shutdown marred Q2 results
PETROR AB: Saudi Arabia US$5.07bn 17.4% US$11.19mn Market cap Free float Avg. daily volume RSI10 Vol th Target price n/a n/a Consensus price 32.18 48.3% over current Current price 21.70 as at 17/8/2011
More informationFamily Zone Cyber Safety Limited (FZO) Company Update. Investment Summary. Investment Highlights. Investment Recommendation
BW EQUITIES RESEARCH 14 March 2017 Family Zone Cyber Safety Limited (FZO) Company Update BUY Rating: Target Price 1 : $0.46 Projected Return: 109% 1 12 month target Company Statistics Share Price (A$)
More informationOz Minerals. Raises copper production outlook A$9.08 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst
AUSTRALIA OZL AU Price (at 7:28, 3 Jan 27 GMT) Neutral A$9.8 Valuation A$ - DCF (WACC 9.%, beta.4, ERP 5.%, RFR 3.3%) 8.48 2-month target A$ 9.3 2-month TSR % +4.6 Volatility Index High GICS sector Materials
More informationAdacel Technologies (ADA)
9 November 2018 Chris Savage 612 8224 2835 Authorisation TS Lim 612 8224 2810 Adacel Technologies (ADA) Bad, but not that bad Recommendation Buy (unchanged) Price $0.88 Target (12 months) $1.50 (previously
More informationFila Korea (081660) Widespread growth potential
Fila Korea (8166) BUY (Maintain), TP: W98, (Maintain) Stock price (Apr 26, KRW) 83,5 Yr to Sales OP EBT NP EPS % chg EBITDA P/E EV/EBITDA P/B ROE Market cap (USD mn) 697 Dec (W bn) (W bn) (W bn) (W bn)
More informationWhitehaven Coal. China outlook drives impairments A$1.04 AUSTRALIA. Event. Impact. Earnings and target price revision.
AUSTRALIA WHC AU Price (at 06:10, 13 Aug 2015 GMT) Neutral A$1.04 Valuation A$ - DCF (WACC 8.0%, beta 1.6, ERP 5.0%, RFR 3.8%) 1.18 12-month target A$ 1.15 12-month TSR % +10.6 Volatility Index High GICS
More informationMultiplex Acumen Property Fund
ASX: MPF Bloomberg: MPF AU Reuters: MPF.AX 03 August 2006 $1.14 FY06 result: Continued delivery of unlisted property earnings growth # of Shares: 207M Market Cap: $230M Current Price: $1.14 % All Ords:
More informationAventus Retail Property Fund
AUSTRALIA AVN AU Price (at 06:10, 29 Apr 2016 GMT) A$2.16 Volatility Index Low GICS sector Real Estate Market cap A$m 741 30-day avg turnover A$m 0.7 Number shares on issue m 343.2 Investment fundamentals
More informationPharmaniaga MARKET PERFORM. 1Q15 Inline but Rich Valuations. Results Note. Price: RM6.91 Target Price: RM6.95. PP7004/02/2013(031762) Page 1 of 5
Pharmaniaga 1Q15 Inline but Rich Valuations By the Kenanga Research Team l research@kenanga.com.my Period 1Q15 Actual vs. Expectations 1Q15 PATAMI of RM31.8m (+21% YoY) came in at 32% and 31% of our and
More informationPremier Investments. Making a move? A$14.18 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA PMV AU Price (at 09:06, 29 Mar 2017 GMT) Outperform A$14.18 Valuation - Sum of Parts A$ 17.19 12-month target A$ 17.92 12-month TSR % +30.4 Volatility Index Low/Medium GICS sector Retailing Market
More informationNational Australia Bank
AUSTRALIA NAB AU Price (at 08:23, 03 Jul 2012 GMT) Outperform A$23.68 Volatility index Low 12-month target A$ 27.66 12-month TSR % +24.9 Valuation A$ - DCF (WACC 12.6%, beta 1.0, ERP 5.0%, RFR 5.8%) 25.14
More informationGeneration Healthcare REIT All about spread Event
AUSTRALIA GHC AU Price (at 04:51, 14 Feb 2015 GMT) Neutral A$1.60 Valuation - Sum of Parts A$ 1.18-1.26 12-month target A$ 1.59 12-month TSR % +5.1 Volatility Index Low GICS sector Real Estate Market cap
More informationCOMPUMEDICS LTD HOLD. CMP Downgrades FY17 Guidance COMPANY UPDATE EVENT KEY TAKE-AWAYS INVESTMENT VIEW
COMPUMEDICS LTD HOLD CMP Downgrades FY17 Guidance Health Care Equipment & Services / Health Care Equipment 7 July 2017 COMPANY UPDATE Ticker CMP Stock Price $0.560 Target Price $0.530 Forecast Capital
More informationCarsales.com. Motoring along nicely A$10.23 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA CRZ AU Price (at 9:48, 18 Feb 15 GMT) Outperform A$1.23 Valuation A$ 12.59 - DCF (WACC 8.1%, beta 1.2, ERP 5., RFR 3.8%, TGR 3.) 12-month target A$ 12.3 12-month TSR % +24.1 Volatility Index
More informationAutomotive Holdings Group
AUSTRALIA AHE AU Price (at 03:28, 13 Feb 2015 GMT) Outperform A$3.82 Valuation - EV/EBITA A$ 3.85-4.34 12-month target A$ 4.34 12-month TSR % +19.6 Volatility Index Low/Medium GICS sector Retailing Market
More informationAxis REIT UNDERPERFORM. Splitting for Better Liquidity. Quick Bites. Price /Ex-Price: RM3.55/RM1.78 TP/Ex-Split: RM3.27/RM1.64
Axis REIT Splitting for Better Liquidity By Sarah Lim l sarahlim@kenanga.com.my News Proposed a 1:2 share split, essentially doubling its unit base from 547.8m to 1.1b units. Comments We were positively
More informationNine Entertainment Co.
AUSTRALIA NEC AU Price (at 06:47, 26 Feb 2015 GMT) Outperform A$2.03 Valuation A$ - DCF (WACC 8.2%, beta 1.2, ERP 5.0%, RFR 3.8%) 2.41 12-month target A$ 2.25 12-month TSR % +15.3 Volatility Index Low/Medium
More informationNewcrest Mining. Strong production result A$21.37 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst
AUSTRALIA NCM AU Price (at 5:37, 27 Oct 216 GMT) Neutral A$21.37 Valuation A$ - DCF (WACC 5.%, beta.8, ERP 5.%, RFR 3.3%) 15.8 12-month target A$ 24. 12-month TSR % +13.9 Volatility Index Medium GICS sector
More informationKorea Zinc (010130) Company Note. 1Q12 preview: Not over until it s over. BUY (Maintain)
Company Note April 1, 212 Korea Zinc (113) 12M rating BUY (Maintain) 12M TP W6, from W6, Up/downside +57% Stock Data KOSPI (Apr 9, pt) 1,997 Stock price (Apr 9, KRW) 381,5 Market cap (USD mn) 6,286 Shares
More informationZain KSA bogged down by high debt
Vol th RSI10 Zain KSA ZAINKSA AB: Saudi Arabia US$2.464bn 48.3% US$16.50mn Market cap Free float Avg. daily volume Target price 7.30 12.31% over current Consensus price 7.62 17.2% over current Current
More informationSomnoMed (SOM) BUY: US channel conflicts abating in Q4. Key points. Risks and catalysts
Date 27 April 2017 Theme Company Update Company SomnoMed (SOM) BUY: US channel conflicts abating in Q4 We maintain a BUY rating and 12-month price target of $4.50 per share. SomnoMed s Q3 update was a
More informationYansab Better than expected results
YANSAB AB: Saudi Arabia US$6.91bn 39.8% US$23.37mn Market cap Free float Avg. daily volume RSI10 Vol th Target price n/a n/a Consensus price 56.00 21.5% over current Current price 46.10 as at 9/2/2011
More informationSandfire Resources. Strong result but guidance light A$6.10 AUSTRALIA. Event. Impact. Earnings and target price revision.
AUSTRALIA SFR AU Price (at 06:37, 29 Jul 20 GMT) Outperform A$6.10 Valuation A$ - DCF (WACC 10.0%, beta 1.7, ERP 5.0%, RFR 3.8%) 8.02 12-month target A$ 8.00 12-month TSR % +35.8 Volatility Index Medium
More informationCSL: Global plasma report
AUSTRALIA AU Price (at 10:49, 11 Apr 2013 GMT) Outperform A$59.35 Volatility index Low 12-month target A$ 63.85 12-month TSR % +9.6 Valuation A$ 59.84 - DCF (WACC 8.5%, beta 0.9, ERP 5.0%, RFR 5.0%, TGR
More informationMNF Group Limited (MNF)
MNF Group Limited (MNF) 16 February 2018 Outperform 1H18 Results: Excessive Sell-off Presents Buying Opportunity $5.14 Chris Reindler creindler@taylorcollison.com.au +61 2 9210 1335 Summary (AUD) Market
More informationSaudi Arabian Mining Co (Maaden AB Equity) Continuing steady performance
Vol mn RSI10 Saudi Arabian Mining Co- Mining Industrial MAADEN AB: Saudi Arabia 29 May 2018 US$17.47bn 35% US$6.79mn Market cap Free float Avg. daily volume Target price 47.60-15.5% over current Current
More information